Literature DB >> 17034776

Suggested functions for prolyl oligopeptidase: a puzzling paradox.

Inger Brandt1, Simon Scharpé, Anne-Marie Lambeir.   

Abstract

Prolyl oligopeptidase (PO, E.C. 3.4.21.26) is a post-proline cleaving enzyme with endopeptidase activity towards peptides not longer than 30 amino acids. It has been purified and characterized from various mammalian and bacterial sources, but despite its thorough enzymological and structural characterization, the exact function of PO remains obscure. Many investigations have addressed the physiological role of this enzyme, mainly by the use of specific PO inhibitors, activity measurements in clinical samples and (neuro)peptide degradation studies. From the combined results emerges a puzzling paradox: how can an intracellular, cytoplasmatic oligopeptidase affect not only the amount of extracellular neuropeptides but also signal transduction and secretion? This report provides a review of the literature on the suggested functions for PO, highlighting possible pitfalls and contradictions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17034776     DOI: 10.1016/j.cca.2006.09.001

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  23 in total

1.  The amino terminus extension in the long dipeptidyl peptidase 9 isoform contains a nuclear localization signal targeting the active peptidase to the nucleus.

Authors:  Daniela Justa-Schuch; Ulrike Möller; Ruth Geiss-Friedlander
Journal:  Cell Mol Life Sci       Date:  2014-02-23       Impact factor: 9.261

2.  Unveiling prolyl oligopeptidase ligand migration by comprehensive computational techniques.

Authors:  Martin Kotev; Daniel Lecina; Teresa Tarragó; Ernest Giralt; Víctor Guallar
Journal:  Biophys J       Date:  2015-01-06       Impact factor: 4.033

3.  Prolyl oligopeptidase induces angiogenesis both in vitro and in vivo in a novel regulatory manner.

Authors:  T T Myöhänen; J Tenorio-Laranga; B Jokinen; R Vázquez-Sánchez; M J Moreno-Baylach; J A García-Horsman; P T Männistö
Journal:  Br J Pharmacol       Date:  2011-08       Impact factor: 8.739

4.  Prolyl oligopeptidase enhances α-synuclein dimerization via direct protein-protein interaction.

Authors:  Mari H Savolainen; Xu Yan; Timo T Myöhänen; Henri J Huttunen
Journal:  J Biol Chem       Date:  2015-01-02       Impact factor: 5.157

Review 5.  The expression of proline-specific enzymes in the human lung.

Authors:  Gwendolyn Vliegen; Tom K Raju; Dirk Adriaensen; Anne-Marie Lambeir; Ingrid De Meester
Journal:  Ann Transl Med       Date:  2017-03

6.  Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis.

Authors:  Jofre Tenorio-Laranga; Francisco Coret-Ferrer; Buenaventura Casanova-Estruch; María Burgal; J Arturo García-Horsman
Journal:  J Neuroinflammation       Date:  2010-04-06       Impact factor: 8.322

7.  Proline-Glycine-Proline (PGP) and High Mobility Group Box Protein-1 (HMGB1): Potential Mediators of Cystic Fibrosis Airway Inflammation.

Authors:  Amit Gaggar; Steven M Rowe; Hardision Matthew; J Edwin Blalock
Journal:  Open Respir Med J       Date:  2010-03-30

8.  Processing of the phalloidin proprotein by prolyl oligopeptidase from the mushroom Conocybe albipes.

Authors:  Hong Luo; Heather E Hallen-Adams; Jonathan D Walton
Journal:  J Biol Chem       Date:  2009-04-23       Impact factor: 5.157

Review 9.  Issues about the physiological functions of prolyl oligopeptidase based on its discordant spatial association with substrates and inconsistencies among mRNA, protein levels, and enzymatic activity.

Authors:  Timo T Myöhänen; J Arturo García-Horsman; Jofre Tenorio-Laranga; Pekka T Männistö
Journal:  J Histochem Cytochem       Date:  2009-05-26       Impact factor: 2.479

10.  Ang II (Angiotensin II) Conversion to Angiotensin-(1-7) in the Circulation Is POP (Prolyloligopeptidase)-Dependent and ACE2 (Angiotensin-Converting Enzyme 2)-Independent.

Authors:  Peter Serfozo; Jan Wysocki; Gvantca Gulua; Arndt Schulze; Minghao Ye; Pan Liu; Jing Jin; Michael Bader; Timo Myöhänen; J Arturo García-Horsman; Daniel Batlle
Journal:  Hypertension       Date:  2019-12-02       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.